课题基金 / 基金详情

Nebraska Center for Nanomedicine

Nebraska Center for Nanomedicine
内布拉斯加州纳米医学中心
批准号:
10441205
负责人:
David Oupicky
金额:
$114.38万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-06-01 至 2023-10-31

项目摘要

项目成果

David Oupicky的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT The multidisciplinary Nebraska Center for Nanomedicine (NCN), established in 2008 with the Center for Biomedical Research Excellence (COBRE) funding, is building a nationally and internationally recognized program of excellence in nanomedicine that combines broad expertise in material, pharmaceutical and biological sciences driven by innovative research. NCN has completed its original objectives and enhanced Nebraska's biomedical research capacity by creating a strategically linked infrastructure of strong research programs and by mentoring a cadre of talented junior faculty to independent success. In the first 9 years of funding, the NCN-funded junior faculty members obtained over $18 million in new research funds, eight NCN trainees have been tenured and/or promoted, eight new junior and senior faculty with expertise relevant to NCN were recruited to the College of Pharmacy. Our graduates have been appointed to editorial boards, serve on review panels, and have countless invitations to present seminars. This NCN COBRE continuation proposal details our plan to maintain a biomedical research center of national prominence and international recognition. The specific aims that move the NCN toward these goals are: 1) continue to expand existing research strengths through the support of collaborative interdisciplinary research and mentorship of junior faculty; 2) strengthen research capabilities, innovation and funding support for investigators affiliated with the NCN; 3) assure sustainability of scientific core facilities that are essential for the continued growth of the Center and serve the research community at large. The realization of these aims will allow the NCN to emerge from Phase III funding as self-sustaining center of research excellence in nanomedicine, with an increased capacity to pursue programmatic support through individual and multi-investigator, program-wide research grants. Through the development and clinical translation of effective nanomedicines for diagnosis and therapy for human diseases, the NCN will ultimately provide significant benefits for the health of Nebraskans and society at large.
期刊论文(31)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.nano.2020.102302
发表时间: 2021-01
期刊: Nanomedicine : nanotechnology, biology, and medicine
影响因子: --
作者: [Zhao Z, Jia Z, Foster KW, Wei X, Qiao F, Jiang H, Jin Y, Li G, Chen N, Zhao G, Thiele GM, Medlin JL, O'Dell JR, Wang D]
通讯作者: Wang D
DOI: 10.1016/j.bpsgos.2021.05.004
发表时间: 2021-09
期刊: Biological psychiatry global open science
影响因子: --
作者: [Elkhatib SK, Moshfegh CM, Watson GF, Schwab AD, Katsurada K, Patel KP, Case AJ]
通讯作者: Case AJ
DOI: 10.1002/jcsm.12864
发表时间: 2022-04
期刊: Journal of cachexia, sarcopenia and muscle
影响因子: --
作者: [Luan Y, Zhang Y, Yu SY, You M, Xu PC, Chung S, Kurita T, Zhu J, Kim SY]
通讯作者: Kim SY
Intraperitoneal siRNA Nanoparticles for Augmentation of Gemcitabine Efficacy in the Treatment of Pancreatic Cancer.
腹膜内siRNA纳米颗粒,用于增强吉西他滨在治疗胰腺癌中的功效。
DOI: 10.1021/acs.molpharmaceut.1c00653
发表时间: 2021-12-06
期刊: MOLECULAR PHARMACEUTICS
影响因子: 4.9
作者: [Tang, Siyuan, Hang, Yu, Ding, Ling, Tang, Weimin, Yu, Ao, Zhang, Chuhan, Sil, Diptesh, Xie, Ying, Oupicky, David]
通讯作者: Oupicky, David
22
    Chloroquine-based polymer particles as oral non-absorbable treatment of inflammatory bowel disease
    Chloroquine-based polymer particles as oral non-absorbable treatment of inflammatory bowel disease
    Development of delivery methods for combination microRNA treatment of alcohol-associated liver disease
    Development of delivery methods for combination microRNA treatment of alcohol-associated liver disease
    国内基金
    海外基金
    层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
    • 批准号:
      2021JJ40433
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2021
    • 负责人:
      孙磊
    • 依托单位:
    寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
    • 批准号:
      32001603
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      24.0万元
    • 批准年份:
      2020
    • 负责人:
      段真珍
    • 依托单位:
    AREA国际经济模型的移植.改进和应用
    • 批准号:
      18870435
    • 项目类别:
      面上项目
    • 资助金额:
      2.0万元
    • 批准年份:
      1988
    • 负责人:
      史树中
    • 依托单位: